Abstract
Research question
Does the FSH receptor (FSHR) genotype influence the results of donor ovarian stimulation
using corifollitropin alfa?
Design
A prospective cohort study was performed including 152 oocyte donor ovarian stimulations:
group 1 (n = 80) using a single dose of 150 µg of corifollitropin alpha; and group 2 (n = 72) using in addition to corifollitropin alpha, continued stimulation using recombinant
FSH 225 IU daily. Allelic discrimination was used to genotype the FSHR p.N680S polymorphism.
Linear regression analysis was performed to study the differences between groups.
Results
No differences in clinical characteristics between genotypes were reported. Overall,
the results of ovarian stimulation were better in oocyte donors with SN and NN genotypes
compared with SS in terms of the number of retrieved oocytes (15.78 versus 10.83;
P = 0.008) and retrieved metaphase II (MII) oocytes (12.34 versus 9.00; P = 0.032). Corresponding differences were also observed in group 1 for the number
of retrieved oocytes (13.83 versus 7.50, P = 0.018) and retrieved MII oocytes (10.24 versus 5.42; P = 0.038). However, in group 2 no significant differences were found for oocytes retrieved
(17.55 versus 13.06, P = 0.064) or MII oocytes (14.25 versus 11.39; P = 0.12).
Conclusions
This study suggests that ovarian stimulation protocols with corifollitropin alfa in
women with the SS genotypes could be associated with fewer oocytes and MII oocytes
retrieved. Despite the fact that corifollitropin alfa has a longer half-life, the
results for the SS genotype do not match those for the other genotypes, so other factors
must be involved. Therefore, to tailor treatments, it would be advisable to genotype
women at p.N680S of the FSHR.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Reproductive BioMedicine OnlineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis.Hum. Reprod. Update. 2018 Sep 1; 24: 599-614
- FSHR polymorphism p.N680S mediates different responses to FSH in vitro.Mol. Cell Endocrinol. 2014 Aug 5; 393: 83-91
- Effect of Genetic Variants of Gonadotropins and Their Receptors on Ovarian Stimulation Outcomes: A Delphi Consensus.Front Endocrinol. (Lausanne). 2022 Feb 1; 12797365
- Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype.J. Clin. Endocrinol. Metab. 2000 Sep; 85: 3365-3369
- Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant.Eur. J. Pharmacol. 2011 Jan 25; 651: 227-233
Biography
Belén Lledó received her PhD in molecular biology from the University of Alicante, Spain. In 2004 she moved to Instituto Bernabeu and is now Director of the Molecular Biology Department. She has received prizes at different congresses and published tens of papers on genetic variants in infertility and preimplantation genetic diagnosis.
Article info
Publication history
Published online: July 27, 2022
Accepted:
July 22,
2022
Received in revised form:
June 30,
2022
Received:
March 4,
2022
Footnotes
Declaration: The authors report no financial or commercial conflicts of interest.
Identification
Copyright
© 2022 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
